EZH2 Inhibitors
1 drugsAbout EZH2
EZH2 (Enhancer of Zeste Homolog 2) is a histone methyltransferase that modifies histone proteins by adding methyl groups, silencing gene expression. This epigenetic modification plays a crucial role in gene regulation and chromatin structure.
EZH2 is a compelling oncology drug target because aberrant activity can lead to uncontrolled cell growth. Currently, there is no genetic evidence directly linking EZH2 to specific diseases.
EZH2 is targeted by one FDA-approved small molecule drug, TAZVERIK, developed by EPIZYME INC for oncology indications. TAZVERIK was first approved in 2020.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Recurrent Follicular Lymphoma with only 2 trials.
- phase1 represents biological uncertainty with 53% completion.
Top EZH2 Drugs
EPIZYME INC is the only company with an approved drug targeting EZH2.
Low competition suggests a high barrier to entry or limited market attractiveness.
EZH2 Clinical Trials 50 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 30 | 7 | 10 | 12 | 41% |
| Phase 2 | 19 | 7 | 5 | 6 | 58% |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 57 clinical trials targeting EZH2.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities